Last updated May 16, 2026
Audience guide · demographic
GLP-1 for Men in 2026
Cardiovascular risk focus, T2D prevalence, testosterone considerations
Verified by James Cole, MD, FACOGHow we review
Men face different GLP-1 considerations than women: higher cardiovascular risk burden, higher T2D prevalence, and emerging data on testosterone interactions with rapid weight loss. The strongest evidence base for cardiovascular outcomes is in male-heavy trial populations.
Who this guide is for
- Profile
- US adult men, ~165M. ~37% have obesity (BMI ≥30). ~12% have T2D — slightly higher than women.
- Common goals
- Cardiovascular risk reduction, T2D control, visceral fat reduction, sleep apnea treatment.
- Constraints
- Lower medical engagement than women — many delay treatment. Testosterone interactions during rapid weight loss are understudied. Cultural barriers around discussing weight with prescribers.
- Coverage reality
- Same commercial/Medicare coverage as women, but men are more likely to qualify for cardiovascular-specific indications (SUSTAIN-6, SELECT trial data) — which can override step therapy.
Ranked for Men
Fit scores reflect this audience’s constraints — not raw clinical efficacy. A drug can be 9/10 overall yet 4/10 for a specific audience because of coverage or cost.
- 1Ozempic9.2/10 fit
Semaglutide approved for type 2 diabetes
SELECT trial: 20% MACE reduction in adults with obesity + established CV disease. Strongest cardiovascular evidence in men — most major trials skew 60-70% male.
- 2Mounjaro8.8/10 fit
Tirzepatide for type 2 diabetes
Superior weight loss + glycemic control. SURPASS-CVOT readout pending — likely to show CV benefit similar to semaglutide.
- 3Zepbound8.5/10 fit
FDA-approved tirzepatide for weight loss
OSA + obesity dual indication especially relevant — men are 2x more likely to have OSA. Dual indication broadens coverage.
- 4Wegovy8.0/10 fit
FDA-approved semaglutide for chronic weight management
SELECT trial data is the FDA basis for cardiovascular indication expansion. Most direct evidence for "weight loss reduces my heart attack risk."
- 5Hims & Hers Weight Loss6.0/10 fit
Compounded semaglutide via telehealth
Reasonable cash-pay option if uninsured. Telehealth bypasses common male reluctance to discuss weight with PCP.
Heads up: Compounded versions lack cardiovascular outcomes data — safer to use brand-name if at high CV risk.
Key considerations
- Cardiovascular risk profile screening
Calculate 10-year ASCVD risk before starting. Men with established CVD or 10-year risk ≥20% may have insurance approval expedited via cardiovascular indication.
- Testosterone may decrease with rapid weight loss
Some men experience testosterone decline during 20%+ body weight reduction. Baseline + 6-month T levels recommended. Not a contraindication but worth tracking.
- Lean mass preservation matters more
Men have higher baseline lean mass — losing it during rapid weight loss has bigger impact on metabolic rate. Resistance training 3x/week + 1.6g/kg protein during titration.
Frequently asked questions
Will Ozempic lower my heart attack risk?
In SELECT trial, semaglutide 2.4mg reduced major adverse cardiovascular events by 20% in adults with overweight/obesity + established CVD. If you have prior heart attack, stroke, or peripheral artery disease, this is the strongest non-statin/non-aspirin cardiovascular intervention.
Does GLP-1 affect testosterone?
Mixed evidence. Some men with obesity see testosterone increase as weight drops (obesity suppresses testosterone). Others see decline during rapid weight loss. Baseline + 6-month checks recommended if you have symptoms.
Are men more likely to develop side effects?
No clear gender difference in GI side effect rates. Men do report nausea less often in self-report studies, but discontinuation rates are similar.
Audience guides synthesize coverage data, clinical recommendations, and demographic-specific constraints. Always verify your specific situation with a licensed prescriber.
Last verified: May 16, 2026